AllPennyStocks.com RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy

BofA called the clinical hold on RGX-121 disappointing and a reversal of July’s progress but kept a $15 price target on the stock.

Other Penny Stock Movers

Financial Tech Junior Surges 18% Following Reaffirmation of US$15.8M Digital Treasury
Quebec Gold Explorer Jumps 16% on C$57M Strategic Backing
$4.5 Million Could Unlock a Major Cannabis Market


Back to Top